patent/UY-34036-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UY-34036-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
filingDate	2012-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_447ac63ead9581386481c80830f02f8f
publicationDate	2012-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	UY-34036-A
titleOfInvention	Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI).
abstract	A pharmaceutical composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) useful for the treatment of colorectal cancer (CRC).
priorityDate	2011-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135403648 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504969 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535834 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505489 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385

Total number of triples: 39.